Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/24/2025 11:46 PDT] Insmed Incorporated (NASDAQ:INSM), Up By 100% ($96.8) From $96.8 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/12/2025 07:33 PDT] INSM Expected to Trade Up After Bullish Patterns Develop
• [06/10/2025 21:22 PDT] Market Maker Surveillance Report. INSM, Winning Stocks With Lowest Price Friction For Tuesday, June 10th 2025
• [06/10/2025 10:30 PDT] Insmed Incorporated (NASDAQ:INSM), Up By 100% ($73.08) From $73.08 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/04/2025 07:14 PDT] INSM Expected to Trade Up After Bullish Patterns Develop
• [05/12/2025 07:17 PDT] INSM Expected to Trade Down After Bearish Patterns Develop
• [05/09/2025 07:36 PDT] INSM Expected to Trade Down Short Term